Centessa Pharmaceuticals (CNTA) Net Cash Flow (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported Net Cash Flow of $950000.0 for Q1 2026, up 100.34% year-over-year from $474185.5 in Q1 2025, and down 89.96% on a QoQ basis from $9.5 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 7 years of Net Cash Flow data on file, last reported at $950000.0 in Q1 2026.
- Quarterly Net Cash Flow rose 100.34% year-over-year to $950000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.3 million (down 245.11% YoY) and the FY2025 annual result came in at -$320.8 million, down 226.32% from the prior year.
- Net Cash Flow eased to $950000.0 in Q1 2026 per CNTA's latest filing, from $9.5 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $269.6 million in Q3 2024 and bottomed at -$276.5 million in Q1 2025.
- The 5-year median for Net Cash Flow is -$38.9 million (2022), against an average of -$31.4 million.
- The widest annual swing landed in 2024, when Net Cash Flow jumped 934.45%; it then slumped 2656.93% in 2025.
- Tracing CNTA's Net Cash Flow over 5 years: stood at -$51.9 million in 2022, then gained by 17.25% to -$43.0 million in 2023, then surged by 65.47% to -$14.8 million in 2024, then surged by 163.75% to $9.5 million in 2025, then plunged by 89.96% to $950000.0 in 2026.
- Per Business Quant, the three latest CNTA Net Cash Flow figures stand at $950000.0 (Q1 2026), $9.5 million (Q4 2025), and $7.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - | 950,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 950,000.00 |
| Mar 31, 2026 | 950,000.00 |
| Dec 31, 2025 | 9.46 Mn |
| Dec 31, 2025 | 9.46 Mn |
| Sep 30, 2025 | 7.07 Mn |
| Sep 30, 2025 | 7.07 Mn |
| Jun 30, 2025 | -60.80 Mn |
| Jun 30, 2025 | -60.80 Mn |
| Mar 31, 2025 | -276.55 Mn |
| Mar 31, 2025 | -276.55 Mn |
| Dec 31, 2024 | -14.84 Mn |
| Dec 31, 2024 | -14.84 Mn |
| Sep 30, 2024 | 269.56 Mn |
| Sep 30, 2024 | 269.56 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Jun 30, 2024 | 9.27 Mn |
| Mar 31, 2024 | -10.03 Mn |
| Mar 31, 2024 | -10.03 Mn |
| Dec 31, 2023 | -42.96 Mn |
| Dec 31, 2023 | -42.96 Mn |
| Sep 30, 2023 | 26.06 Mn |
| Sep 30, 2023 | 26.06 Mn |
| Jun 30, 2023 | -115.15 Mn |
| Jun 30, 2023 | -115.15 Mn |
| Mar 31, 2023 | -134.17 Mn |
| Mar 31, 2023 | -134.17 Mn |
| Dec 31, 2022 | -51.92 Mn |
| Dec 31, 2022 | -51.92 Mn |
| Sep 30, 2022 | -38.88 Mn |
| Sep 30, 2022 | -38.88 Mn |
| Jun 30, 2022 | -60.04 Mn |
| Jun 30, 2022 | -60.04 Mn |
| Mar 31, 2022 | -50.18 Mn |
| Mar 31, 2022 | -50.18 Mn |
| Dec 31, 2021 | 17.94 Mn |
| Dec 31, 2021 | 17.94 Mn |
| Sep 30, 2021 | -35.21 Mn |
| Sep 30, 2021 | -35.21 Mn |
| Jun 30, 2021 | 311.80 Mn |
| Jun 30, 2021 | 311.80 Mn |
| Mar 31, 2021 | 293.77 Mn |
| Mar 31, 2021 | 293.77 Mn |
| Dec 31, 2020 | -2.00 Mn |
| Dec 31, 2020 | -2.00 Mn |
| Sep 30, 2020 | -1.82 Mn |
| Sep 30, 2020 | -1.82 Mn |